Trending

CNS

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with

X

US, EU reviews start for Novartis’ Ocrevus rival ofatumumab

https://pharmaphorum.com/news/us-eu-reviews-start-for-novartis-ocrevus-rival-ofatumumab/

Finding the big picture for Alzheimer’s

Finding the big picture for Alzheimer’s

The $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’

X

Finding the big picture for Alzheimer’s

https://pharmaphorum.com/r-d/views-analysis-r-d/finding-the-big-picture-for-alzheimers/

A bright future for CNS and Alzheimer’s?

A bright future for CNS and Alzheimer’s?

Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare

X

A bright future for CNS and Alzheimer’s?

https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/

Regeneron and Alnylam announce $1bn collaboration

Regeneron and Alnylam announce $1bn collaboration

Regeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and

X

Regeneron and Alnylam announce $1bn collaboration

https://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s CNS exit takes the form of a biotech spinout

Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of

X

Pfizer’s CNS exit takes the form of a biotech spinout

https://pharmaphorum.com/news/pfizers-cns-exit-takes-the-form-of-a-biotech-spinout/

Tysabri failure in stroke a setback for Biogen

Tysabri failure in stroke a setback for Biogen

Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed.

X

Tysabri failure in stroke a setback for Biogen

https://pharmaphorum.com/news/tysabri-failure-stroke-setback-biogen/

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.

X

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

https://pharmaphorum.com/views-and-analysis/janssen-mental-health-psychiatry/

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

David Epstein, who left his job as head of Novartis’ pharma division in May, has joined Remedy Pharmaceuticals

X

Ex-Novartis chief Epstein joins Remedy Pharmaceuticals

https://pharmaphorum.com/news/ex-novartis-chief-epstein-joins-remedy-pharmaceuticals/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com